|Systematic (IUPAC) name|
|CAS Registry Number|
|Molecular mass||585.55 g/mol|
Cadazolid is an experimental antibiotic of the oxazolidinone class made by Actelion Pharmaceuticals Ltd. which is effective against Clostridium difficile, a major cause of drug resistant diarrhea in the elderly. Current drug treatments for this infection involve orally delivered antibiotics, principally fidaxomicin, metronidazole and vancomycin; the last two drugs are the principal therapeutic agents in use, but fail in approximately 20 to 45% of the cases. The drug is in Phase III trials. The drug works by inhibiting synthesis of proteins in the bacteria, thus inhibiting the production of toxins and the formation of spores.
- Boschert, Sherry (19 Sep 2012). "Promising C. difficile Antibiotic in Pipeline". Internal Medicine News. International Medical News Group. Retrieved 22 May 2013.
- "Cadazolid". .actelion.com. Retrieved 2013-05-22.
- "Anaerobe - In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden". Anaerobe 20: 32–35. 2013-02-26. doi:10.1016/j.anaerobe.2013.02.003. Retrieved 2013-05-22.
|This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.|